진원생명과학

011000KOSPI의약품 제조업

27.7 / 100

Reference Date: 2026-04-13

Financial Score8.0 / 40

News Sentiment9.7 / 25

Momentum6.0 / 20

Disclosure4.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 34.7% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Jinwon Pharmaceuticals focuses on biopharmaceutical CDMO services and next-generation biopharmaceutical development. The CDMO business produces cGMP-grade plasmid DNA for gene therapies and DNA vaccines, while also advancing mRNA vaccine and therapeutic development through technology licensing. In new drug development, the company has completed clinical trials for DNA vaccines targeting MERS, Zika, and SFTS, and is expanding research through global partnerships.

Number of Employees

52people

Average Salary

70.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 16.864.0Point

PBR

—Industry Average 1.133.5Point

ROE

-49.25Industry Average 2.940.0Point

Well below industry avg

Debt Ratio

6572916520800.00Industry Average 53.870.0Point

122014414716.9x industry avg (risky)

Trend 2022~20240.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼14.3% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼4.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -51.2% (improving, 2yr)

Detailed News Sentiment

9 totalPositive 0Neutral 1Negative 3Average Sentiment Score 25

Neutral
'설마 내 종목도?'...60여개사 무더기 상폐위기 [마켓딥다이브]
Negative
정기주총 앞두고 감사보고서 지각 여전…공포에 떠는 개미들
진원생명과학을 포함한 여러 상장사들이 정기 주주총회를 앞두고 감사보고서 제출을 지연하여 주주들의 우려를 사고 있으며, 비적정 감사의견 시 상장폐지 사유가 될 수 있습니다.
Negative
주총 앞두고 감사보고서 지각 속출...지난해 지각 기업 절반은 상폐 사...
진원생명과학은 감사보고서 제출 지연 공시를 낸 상장사 중 하나로, 지난해 감사보고서를 지각 제출한 기업 중 절반 가까이가 상장폐지 사유에 해당하는 '의견 거절' 감사의견을 받아 투자자들의 우려가 커지고 있습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 710Won52-week high 3,78552-week low 699

1-month return0.0Point

1m -34.68% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

19 totalPositive 0Neutral 17Negative 2

Negative불성실공시법인지정2026-04-09
Neutral감사보고서제출2026-04-07
Neutral사업보고서 (2025.12)2026-04-07
Neutral자본잠식50%이상또는매출액50억원미만사실발생2026-04-07
Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-04-02